Retraction Notice to “Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats” [Biomed. Pharmacother. 104 (2018) 127–136, (S0753332218315385), (10.1016/j.biopha.2018.05.020)];Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats

Biomedicine and Pharmacotherapy

Volumn 104, Issue , 2018, Pages 127-136

  Haddadi, Rasool ^a,b   Nayebi, Alireza Mohajjel ^c,d   Eyvari Brooshghalan, Shahla ^b  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Neurodegeneration; Oxidative stress; Parkinson s disease; Silymarin; TLR

Indexed keywords

APOMORPHINE; CASPASE 3; CATALASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; OXIDOPAMINE; PROTEIN BAX; PROTEIN BCL 2; SILYMARIN; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TLR4 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; MALE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; METABOLISM; PARKINSON DISEASE; SUBSTANTIA NIGRA; WISTAR RAT;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; GLUTATHIONE REDUCTASE; MALE; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SILYMARIN; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TOLL-LIKE RECEPTOR 4;

EID: 85047089793     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2023.116044     Document Type: Erratum

References (40)

1. Panaro, M.A., Lofrumento, D.D., Saponaro, C., De Nuccio, F., Cianciulli, A., Mitolo, V., Nicolardi, G., Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease. Immunopharmacol. Immunotoxicol. 30:4 (2008), 729–740.
2. Takeda, K., Kaisho, T., Akira, S., Toll-like receptors. Annu. Rev. Immunol. 21:1 (2003), 335–376.
3. Okun, E., Griffioen, K.J., Lathia, J.D., Tang, S.-C., Mattson, M.P., Arumugam, T.V., Toll-like receptors in neurodegeneration. Brain Res. Rev. 59:2 (2009), 278–292.
4. Halliwell, B., Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 97:6 (2006), 1634–1658.
5. Andersen, J.K., Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10 (2004), 18–25.
6. Bonda, D.J., Wang, X., Perry, G., Nunomura, A., Tabaton, M., Zhu, X., Smith, M.A., Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59:4–5 (2010), 290–294.
7. Sastry, P., Rao, K.S., Apoptosis and the nervous system. J. Neurochem. 74:1 (2000), 1–20.
8. Tatton, W.G., Chalmers-Redman, R., Brown, D., Tatton, N., Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53:S3 (2003), S61–S72.
9. Ekshyyan, O., Aw, T.Y., Apoptosis: a key in neurodegenerative disorders. Curr. Neurovasc. Res. 1:4 (2004), 355–371.
10. Yuan, J., Yankner, B.A., Apoptosis in the nervous system. Nature 407:6805 (2000), 802–809.
11. Tatton, N.A., Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166:1 (2000), 29–43.
12. Radko, L., Cybulski, W., Application of silymarin in human and animal medicine. J. Pre-Clin. Clin. Res., 1(1), 2007.
13. Nencini, C., Giorgi, G., Micheli, L., Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 14:2 (2007), 129–135.
14. Haddadi, R., Mohajjel Nayebi, A., Brooshghalan, S.E., Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats. Neurosci. Lett. 555 (2013), 106–111.
15. Haddadi, R., Nayebi, A.M., Farajniya, S., Brooshghalan, S.E., Sharifi, H., Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study. DARU J. Pharm. Sci., 22(1), 2014, 38.
16. Haddadi, R., Brooshghalan, S.E., Farajniya, S., Nayebi, A.M., Sharifi, H., Short-term treatment with silymarin improved 6-OHDA-induced catalepsy and motor imbalance in hemi-parkisonian rats. Adv. Pharm. Bull. 5:4 (2015), 463–469.
17. Paxinos, G., Watson, C., The Rat Brain in Stereotaxic Coordinates. 2007, Academic Press.
18. Kheradmand, A., Nayebi, A.M., Jorjani, M., Khalifeh, S., Haddadi, R., Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: possible involvement of oxidative stress and inflammatory cytokines. Neurosci. Lett. 627 (2016), 7–12.
19. Moron, M.S., Depierre, J.W., Mannervik, B., Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim. Biophys. Acta (BBA) Gen. Subj. 582:1 (1979), 67–78.
20. Sharifi, H., Nayebi, A.M., Farajnia, S., Haddadi, R., Effect of buspirone, fluoxetine and 8-OH-DPAT on striatal expression of Bax, caspase-3 and Bcl-2 proteins in 6-hydroxydopamine-induced hemi-parkinsonian rats. Adv. Pharm. Bull., 5(4), 2015, 491.
21. Schwarting, R., Huston, J., The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50:2 (1996), 275–331.
22. Floyd, R.A., Antioxidants, oxidative stress, and degenerative neurological disorders. Exp. Biol. Med. 222:3 (1999), 236–245.
23. Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., Verna, J.-M., Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2 (2001), 135–172.
24. Kheradmand, A., Mohajjel Nayebi, A., Jorjani, M., Haddadi, R., Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats. Iran. J. Basic Med. Sci. 19:5 (2016), 490–496.
25. Haddadi, R., Poursina, M., Zeraati, F., Nadi, F., Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc. Inflammopharmacology, 2018, 1–12.
26. El-Awady, E.-S.E., Moustafa, Y.M., Abo-Elmatty, D.M., Radwan, A., Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. Eur. J. Pharmacol. 650:1 (2011), 335–341.
27. El-Shitany, N.A., El-Haggar, S., El-Desoky, K., Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem. Toxicol. 46:7 (2008), 2422–2428.
28. Ochu, E.E., Rothwell, N.J., Waters, C.M., Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J. Neurochem. 70:6 (1998), 2637–2640.
29. He, Y., Lee, T., Leong, S., 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res. 858:1 (2000), 163–166.
30. Reed, J.C., Mechanisms of apoptosis. Am. J. Pathol. 157:5 (2000), 1415–1430.
31. Troy, C.M., Salvesen, G.S., Caspases on the brain. J. Neurosci. Res. 69:2 (2002), 145–150.
32. Antonsson, B., Martinou, J.-C., The Bcl-2 protein family. Exp. Cell Res. 256:1 (2000), 50–57.
33. Patel, N., Joseph, C., Corcoran, G.B., Ray, S.D., Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol. Appl. Pharmacol. 245:2 (2010), 143–152.
34. Jiang, Y.-y., Wang, H.-j., Wang, J., Tashiro, S.-i., Onodera, S., Ikejima, T., The protective effect of silibinin against mitomycin C-induced intrinsic apoptosis in human melanoma A375-S2 cells. J. Pharmacol. Sci. 111:2 (2009), 137–146.
35. Raza, S.S., Khan, M.M., Ashafaq, M., Ahmad, A., Khuwaja, G., Khan, A., Siddiqui, M.S., Safhi, M.M., Islam, F., Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: a behavioral, biochemical and immunohistological study in Wistar rats. J. Neurol. Sci. 309:1 (2011), 45–54.
36. Manna, S.K., Mukhopadhyay, A., Van, N.T., Aggarwal, B.B., Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. J. Immunol. 163:12 (1999), 6800–6809.
37. Taghiabadi, E., Imenshahidi, M., Abnous, K., Mosafa, F., Sankian, M., Memar, B., Karimi, G., Protective effect of silymarin against acrolein-induced cardiotoxicity in mice. Evid. Based Complement. Altern. Med., 2012, 2012.
38. Singhal, N.K., Chauhan, A.K., Jain, S.K., Shanker, R., Singh, C., Singh, M.P., Silymarin-and melatonin-mediated changes in the expression of selected genes in pesticides-induced Parkinsonism. Mol. Biochem. 384:1–2 (2013), 47–58.
39. Sharifi, H., Nayebi, A., Farajnia, S., Haddadi, R., Effect of chronic administration of buspirone and fluoxetine on inflammatory cytokines in 6-hydroxydopamine-lesioned rats. Drug Res. (EFirst) 65:08 (2015), 393–397.
40. Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P.P., Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci. Rep., 3, 2013.